Health Kick Podcast: Neurizon gears up for 2025
Neurizon Therapeutics recently received EMA orphan designation for NUZ-001 to treat ALS and filed an FDA IND application to begin a phase 2/3 HEALEY ALS trial, pending FDA review.
News
Santa didn’t rally but these stocks fared okay in December
The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again. But… it wasn’t ALL bad, as these 50 stocks proved.
ASX November Health Winners
The ASX 200 Health Care Index rose 2.89% in November and is up 9.54%. ‘Momentum is starting to return,’ says Morgans healthcare analyst Scott Power.
Iron ore slump drags ASX, gold stocks fall
The ASX ended Monday flattish, while uranium miners rose after Cameco halted production. Also… news just in – Trudeau looks set to quit.
Summit soars on acquisition of Brazilian play
Summit Minerals led resource gainers on Monday after signing a deal to acquire the Mundo Novo niobium and rare earths project in central Brazil.
ASX keeps rolling as Nasdaq rebounds
ASX lifts on Wall Street bounce, energy stocks rise and Insignia jumps on takeover bid.
Gold stocking stuffers
Stockhead has filled your stocking with several ASX gold juniors that remain undervalued despite record gold prices.
Morgans’ ASX health picks for 2025
Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.
Gas plays to watch in 2025
These ASX-listed gas companies have pending news flow of significance coming in 2025.
Analyst spots two top ASX stocks for growth
Morningstar picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.
How major commodities fared in 2024
Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a tumultuous 2024.
Economics for BCM’s ‘unique’ REE project coming soon
Brazilian Critical Minerals is looking forward to a big 2025 in which the market sees the value of its Ema rare earths project.
New rules force ASX firms to reveal climate plan
Aussie companies must report climate risks from 2025, giving investors more transparency on what’s coming.
Gold already hitting high notes in 2025
Gold prices rose ~1.5% on Thursday and Friday, following on from a ~26% annual gain, the metal’s ninth best in 50 years.
Uranium surges on ASX as Cameco halts output
The ASX rose on Friday on oil and uranium supply issues. Meanwhile the Aussie dollar slipped as gold and real estate climbed.
Elevate amongst uranium plays on the rise
Elevate Uranium, Bannerman Energy and Lotus Resources have made some of the biggest gains amongst the uranium companies rising today.
ASX rises, Paladin and Boss Energy soar
The ASX is edging up at lunch on Friday despite a Wall Street slump. Energy stocks have surged, the Aussie dollar has dipped and RBA rate cuts are at risk.
Uranium players rise on Kazakh woes
ASX uranium plays are rising amid hopes a Kazakh mine delay will lead to higher prices, plus Jervois and Fortescue.
December’s top 50 resources stocks
Aldoro led resources stock gains in December on strong niobium sampling results at its Kameelburg project in Namibia.
Bullish crypto eyes turn to Trump’s inauguration
December was a topsy turvy month for crypto, but growing stablecoin reserves could hint at a fresh rally as Trump’s inauguration approaches.
Famed local drug developer launches new biotech fund
The co-developer of one of only a few US-approved, locally-developed drugs, Professor Andrew Wilks has created a new fund to sniff out more winners.
ASX rebounds as Brainchip soars
Aussie shares moved up on Thursday. Energy stocks led, Lendlease dipped, Brainchip soared, and the AUD hit a two-year low.
Azure’s former MD joins junior Lycaon
Tony Rovira was at the reins when Azure’s world-class Azure deposit was taken over by Hancock and SQM in a $1.7bn deal.
ASX up, Tesla explodes in Vegas, AUD drops
The ASX is on the up on Thursday, while Lendlease sells UK unit, Brainchip rallies again, the Aussie dollar drops and home prices slip.
Some mining project names are pure comedy gold
Settling on a name for a mineral deposit isn’t quite as important as naming a child but it’s clear some choose to be more creative than others, writes Kristie Batten.
Expert outlooks for markets in 2025
Donald Trump’s re-election as US president adds to uncertainty for the year ahead, according to leading analysts who have given their forecasts for global markets in 2025.
ASX miners who joined the $500m club
Gold miners were the big movers as ten ASX resources companies cleared a $500m market cap to join our Monsters of Rock club.
ASX healthcare’s 2024 winners and losers
Morgans analyst Iain Wilkie said 2024 was “pretty patchy” for the ASX healthcare sector, which underperformed broader markets.
A decent year, but ASX fizzles out for 2024
The ASX slipped again on 2024’s final day. It was still the best year since 2021 for the local bourse, however.
Resources Top 5: Speeding tickets and no news moves ring in the new year
5EA Advanced Materials has fended off a speeding ticket, while gold and Greenland explorers are among the no-news movers.
Pro Medicus notches another US contract win
A fresh $15 million deal takes radiology house Pro Medicus’s US contract wins in 2024 to at least $580 million.
Top 100 resources stocks for 2024
Numerous small caps delivered significant returns despite a tough market cycle. Here’s a collection of the top winners and gainers for 2024.
How ASX bulks performed in 2024
The ASX’s big iron ore and coal stocks let down the local market in 2024, but there were a handful of bulk winners.
ASX slips but Brainchip up 68pc in 5 days
ASX 200 drops as Santa rally fades, but energy, gold and Brainchip shine.
Gold M&A again leads the headlines
Maximus Resources has received a 7c per share takeover offer from neighbour Astral in a move that could combine the companies and their resources in the region.
Stocks fall on US debt ceiling fears
ASX falls after Wall Street sell-off, with Nvidia, Microsoft sliding and Bitcoin tumbling as traders take profits.
Telix files for key US approval
Telix CEO Chris Behrenbruch has been awarded a 68% base pay rise ahead of expected FDA approval of its kidney cancer diagnosis tool.
Gold M&A on the cards
With two juniors entering trading halts, more gold M&A could be coming in 2024. With prices near record highs, 2025 looks even wilder.
Felix sets ambitious antimony strategy
Felix Gold has laid its antimony ambitions bare, targeting 2025 restart of historic Scrafford mine in Alaska after this year’s price spike.
More small cap gems set to shine in 2025
After a stellar 2024 for recovering small to mid caps sector, our experts scour the sector for more overlooked nuggets.
Small caps poised to star in 2025
There are no dead-certs in small-cap investing, but here are some plays that just might rise and shine in 2025.
Bell Potter’s 2025 mining stocks to watch
Gold benefits from rate cuts, while copper shows long-term promise, with Bell Potter backing both for 2025.
2024’s top ASX gas performers
The gas market in 2024 offered both challenges and opportunities, here are the companies that threaded the needle and performed well.
Legally, share ownership may not be what you think
Investors should ask questions about custodial-based share arrangements by which they do not have legal ownership.
ASX up, Appen and Novonix race ahead
The ASX rallied on commodities boost on December 27. BrainChip and DroneShield led, while 2025 volatility looms with key risks.
Japan joins mission critical
The owner of a fluorspar deposit in northern WA says Japan’s Sumitomo could take a 22.5% stake in a $60m JV to develop the project.
ASX rises as Brainchip and Droneshield soar
ASX rallies on commodities, Brainchip and Droneshield soar. Meanwhile Aussies might well have spent about $1.3bn on Boxing Day.
These IPOs stole the stage in 2024
Out of 27 local IPOs in 2024, two resources plays, an engineering stock, a Mexican food chain and a wool clothing company topped the charts.
Race heads to clinic with cancer heart protection trial
Race Oncology hopes its drug candidate can protect the heart from the dangerous effect of chemotherapy.
More lithium M&As on the cards in 2025
Research firm Allens says more M&A activity is expected in 2025, confirming lithium’s positive long-term outlook.
ASX up, Avita soars, St Barbara slumps
ASX keeps the rally going on Christmas Eve as Avita jumps, St Barbara tanks. Meanwhile Bitcoin dips but ‘altcoins’ get some love.
Arcadium goes to Rio, Burley kicks iron ore goals
Arcadium shareholders approve $10 billion takeover by Rio Tinto, with the mining giant hoping to secure its lithium prize by mid-2025.
2025’s hottest resources stocks: Pt 2
In the second part of our end-of-year special, seven more fundies and analysts give their commodity and resources stock picks for 2025.
2025’s hottest resources stocks: Pt 1
In the first part of our end-of-year special, seven fundies and analysts give their commodity and resources stock picks for 2025.
3 key megatrends to shape investing
Key investment ‘megatrends’ to watch out for in 2025? Geopolitical tensions/rising defence spending, energy demand and AI growth.
Road to 2025: QMines
In this episode, host Sarah Hughan recaps the past 12 months for Queensland explorer QMines and its impressive projects.
Vanadium play QEM up on govt backing
QEM snares Coordinated Project status for its Julia Creek vanadium and oil shale project; Leeuwin shareholders like Marda gold deal.
ASX climbs closer to Christmas
Investors have seemingly been taking advantage of pre-Christmas sales, with the ASX 200 closing to the upside by a very festive 1.67%.
Road to 2025: Harvest Technology
Sarah Hughan covers Harvest Technology Group which has seen an exciting 2024 with a new CEO, a pathway to profitability and new shareholders.
ASX up 1pc as bargain hunters swoop
ASX dodges CHESS disaster, rises 1pc as bargain hunters swoop in across all sectors.
Wildcat top stock for contrarian lithium bet
Barry FitzGerald says if the consensus has gold and uranium stocks leading the way in 2025, lithium could surprise.
Bell Potter’s top tech and health stocks for 2025
Australian stockbroking and financial advisory firm Bell Potter is bullish on these tech stocks and healthcare stocks for 2025.
No Christmas break for Legacy in its tier one quest
Junior explorer Legacy Minerals believes its large landholding and tier one partners position it as having a strong chance of making a major discovery.
How to tap the $33 billion pet care market
The listed Mad Paws and Apiam Animal Health offer rare listed exposures to the lucrative and growing pet care sector.
Private credit poised for growth in 2025
Private credit is set to continue its strong growth trajectory in 2025 according to experts in the sector.
Canary Capital thinks these gold stocks could fly
Canary Capital’s Paul Hart remains bullish on gold and outlines why he’s chosen these three ASX stocks as potentially winning picks for investors.
Leeuwin surges on Marda gold deal
Leeuwin climbs after acquiring the Marda project from Ramelius, while Iltani pops up with high-grade drill results at Orient.
Gold bulls watching more than US rates
MineLife’s Gavin Wendt says gold is his key commodity pick for 2025, with analysts not just basing their bets on interest rates.
ASX hits three-month low
The local bourse hit a three-month low on Friday as CBA led the banks down, Mesoblast gave back some of its 50pc gain and the ASX had a CHESS outage.
Clean energy’s on track – can we speed it up?
Clean energy is moving ahead, believe experts, but with key tech still in diapers, hitting ultimate climate goals is no sure thing.
This biotech fell off its perch this week
Percheron fell ~90% in a week Morgans analyst Scott Power described as one of both good and bad news for the ASX healthcare sector.
Iron ore decline in Canberra crystal ball
Federal government forecasters are continuing to go bearish on iron ore prices, as Australia plans for lower bulk commodity prices.
ASX drops more as Bitcoin falls below US$97k
The ASX has taken another hit on Friday as the Fed’s cautious outlook lingers. Bitcoin has slid below US$97k and gold miners are in retreat.
Radiopharm’s first in-human study
Sarah Hughan details Radiopharm Theranostics’ first in-human study approval for the treatment of breast and gastric cancers.
Caution ahead as Fed turns hawkish
The Fed’s latest interest rate cut of 25 basis points MAY well be its last for the foreseeable future. So… now how to position as investors?
ASX silver stocks to fill your stocking
The ASX silver sector is blossoming after prices shot up almost 30% this year. Stockhead finds the pick of the bunch for your Xmas stocking.
Smart money flows to resources
Resources stocks in may have been sold off this year, but corporate activity shows majors and strategics are planning for the next boom.
ASX graphite stock calls cops on China
Novonix champions investigation into whether China is dumping graphite to force out US competitors.
Patriot recharges on VW lithium deal
Patriot, Cosmos lead gains with big developments in Canadian and Bolivian lithium, while Anax and Trek were among the no-news gainers.
ASX sinks on rate fears, Mesoblast up 52pc
The ASX hit a six-week low on a red Thursday, after the US Federal Reserve struck a more hawkish interest rates-related tone than expected.
Original URL: https://www.news.com.au/finance/business/stockhead/news/page/8